For Immediate Release
Burlington, MA, November 1, 2005– qaSignature, specialists in the development of automation testing solutions for rapid quality assurance testing of software applications reported today that it has helped Ardais Corporation’s bioinformatics group successfully introduce an agile software development methodology to the development and testing of the Ardais Biospecimen Management System. The methodology requires complete regression testing of each software build, which is only possible with automated testing. qaSignature is the market leader in maintainable automation testing solutions.
“The collaboration between the Ardais software development team and qaSignature has brought immediate tangible results that quadrupled development team productivity, an accomplishment for which Ardais received a CIO 100 Award in 2003. It will also translate into savings for future software development” commented Gregg Yost, Ardais’ VP of Engineering. Dr. Yost estimates that for the next 12 months of development, the investment made in an agile methodology with automated testing and the ability to test applications overnight with virtually no manpower will translate into $1,000,000 savings.
qaSignature’s history with agile methodologies and test automation shows that the benefits go beyond cash savings. These improvements also translate into opportunity benefits that derive from the ability to bring the same high quality product to the market in almost half the time. “We demonstrated that our methodology produces predictable results for our clients” said Vlad Shamis, CEO and Founder of qaSignature. “My compliments to the Ardais Team for their energy and commitment to this effort.”
qaSignature has introduced a foolproof, low risk process for getting started with Automation. It’s called the Diagnostic & Proof Of Concept. A $5,000 investment provides the client an opportunity to evaluate for themselves the potential the qaSignature Methodology will provide for their development efforts. They can review the results of Test Automation built to work with their own applications. Follow This Link: http://www.qasignature.com/offers/concept.htm, For An Overview Of Our Proof Of Concept Offer.
Ardais Corporation addresses all the challenges of biospecimen management, allowing researchers to focus solely on the research discoveries and clinical developments that will advance molecular medicine. As a pioneer in best practices for this field, Ardais has developed a proprietary, end-to-end solution that permits academic and commercial scientists and clinicians to standardize and organize their biospecimen collection, archiving, and access, thereby enhancing and accelerating research and clinical development.
The Ardais Biospecimen Management System, encompassing biological, informatics and engineering expertise, is a suite of software applications, operating procedures, proprietary supplies, and data standards that integrate clients’ biorepository operations at one or multiple geographic sites.
For more information please contact:
Vlad Shamis
vshamis@qasignature.com
www.qasignature.com
(857) 229-1060
Please visit: www.ardais.com.
«« Back to qaSignature News“The proof of concept demonstrated the applicability of applying the qaSignature QA Automation Methodology to our Agile Development Process.”
- Keith Hillyard, Custom Engineering SQA Manager, Kronos
“The collaboration between the Ardais software development team and qaSignature brought immediate tangible results that quadrupled development team productivity, an accomplishment for which Ardais received a CIO 100 Award in 2003. Our investment made in automation and the ability to test applications overnight with virtually no manpower will translate into $1,000,000 savings in the next 12 months.”
- Martin Ferguson, Senior Vice President of Bioinformatics, Ardais
“Our quickest release takes about 3 months. qaSignature allowed us to release this product in under 2 months for a savings of 6 people for 5 weeks or 150 mandays.”
- Dennis Knoetgen, Director, MatrixOne